ATHE · NASDAQ · Biotechnology

Alterity Therapeutics (ADR) (ATHE)

Develops ATH434, a clinical candidate for multiple system atrophy and related Parkinsonian disorders.

$3.78
vs last close+0.00 (+0.03%)